Latest Breaking News On - Head of development at sangamo - Page 1 : comparemela.com

Sangamo Therapeutics, Inc : Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease

Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above

Aaron feingoldRob schottJaya ganeshExchange commissionIcahn school of medicine at mount sinaiDrug administrationHead of development at sangamoEuropean medicines agencySangamo therapeutics incEvents presentationsIcahn schoolMount sinaiOrphan drugOrphan medicinal productEuropean medicinesAnnual report

Pfizer: Phase 1/2 Results Show Bleeding Control In Highest Dose Cohort After Hemophilia A Gene Therapy

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years

Rob schottPfizer incDrug administrationHead of development at sangamoSangamo therapeutics incSangamo therapeutics

Gene therapy sustains bleeding control in haemophilia A trial

Gene therapy sustains bleeding control in haemophilia A trial
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United statesTseng chengRob schottEuropean medicines agencyHead of development at sangamoDrug administrationAmerican society for hematology annual meetingSangamo therapeuticsAmerican societyHematology annual meetingSenior vice presidentChief scientific officerPfizer rareOrphan drugFast trackOrphan medicinal product

Sangamo Therapeutics, Inc : Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood

United statesAaron feingoldRob schottKarin knobeExchange commissionHead of development at sangamoAmerican society for hematology annual meetingSangamo therapeutics incHead of developmentAmerican societyHematology annual meetingRare diseasesRare blood disordersFast track designationOrphan medicinal productAnnual report

Sangamo Therapeutics, Inc : Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec

United statesAaron feingoldSengh chengRob schottDrug administrationAmerican society for hematology annual meetingSangamo therapeutics incExchange commissionPfizer incEuropean medicines agencyHead of development at sangamoSangamo therapeuticsAmerican societyHematology annual meetingSenior vice presidentChief scientific officer